NCT04629729 2026-03-19FT819 in Subjects With B-cell MalignanciesFate TherapeuticsPhase 1 Active not recruiting54 enrolled
NCT04673617 2025-06-11AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaArtiva Biotherapeutics, Inc.Phase 1/2 Active not recruiting45 enrolled
NCT04023071 2023-10-26FT516 in Subjects With Advanced Hematologic MalignanciesFate TherapeuticsPhase 1 Terminated72 enrolled
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled